Group 1 - The company announced its first share buyback of 270,000 A-shares through centralized bidding on September 4, 2025 [1] - The repurchased shares account for 0.004% of the company's total share capital [1] - The highest transaction price was 67.97 CNY per share, while the lowest was 67.75 CNY per share, with a total payment of 18,313,920 CNY (excluding transaction fees) [1] Group 2 - The buyback complies with relevant laws and regulations as well as the company's established share repurchase plan [1]

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for clinical trials of HRS-4729 injection, a self-developed peptide drug aimed at improving metabolic regulation and weight loss [1] Group 1: Product Development - HRS-4729 injection is a triple receptor agonist targeting GLP-1R, GIPR, and GCGR, which enhances energy expenditure and lipid metabolism compared to dual-target products [1] - The drug aims to regulate glucose and lipid metabolism while suppressing appetite, leading to better weight loss and reduction of liver fat [1] - As of now, there are no similar products approved for market release domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for HRS-4729 injection has reached approximately 39.62 million yuan [1]

恒瑞医药（600276）(01276)发布公告，2025年9月4日，公司通过集中竞价交易方式首次回购A股股份27 万股，已回购股份占公司总股本的比例为0.004%，成交的最高价为67.97元/股，最低价为67.75元/股， 已支付的总金额为1831.39万元(不含交易费用)。上述回购符合相关法律法规的规定及公司既定的回购股 份方案。 ...

Group 1 - The company, Heng Rui Medicine (01276), announced its first share buyback of 270,000 A-shares through centralized bidding on September 4, 2025 [1] - The repurchased shares account for 0.004% of the company's total share capital [1] - The highest transaction price was 67.97 yuan per share, while the lowest was 67.75 yuan per share, with a total payment of 18.3139 million yuan (excluding transaction fees) [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-4729 injection, a self-developed peptide drug aimed at improving metabolic regulation and weight loss [1] Company Summary - Heng Rui Medicine and its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. have announced the approval for clinical trials of HRS-4729 injection [1] - HRS-4729 is a triple receptor agonist targeting GLP-1R, GIPR, and GCGR, which is expected to enhance energy expenditure and lipid metabolism compared to dual-target therapies [1] Industry Summary - The drug is positioned to better regulate glucose and lipid metabolism, suppress appetite, and promote fat oxidation, potentially offering improved weight loss and liver fat reduction effects [1]

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Ruishi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of RSS0393 ointment, which will commence shortly [1] Group 1: Product Development - RSS0393 ointment is a self-developed product by Heng Rui Medicine, containing a PDE4 small molecule inhibitor [1] - The ointment is designed to alleviate tissue damage and inflammation by inhibiting PDE4 activity in various cells upon application [1]

江苏恒瑞医药股份有限公司 关于首次回购公司 A 股股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/8/21 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 月 8 | 8 | 20 | 日~2026 | 年 | 月 | 19 日 | | 预计回购金额 | 100,000万元~200,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 27万股 | | | | | | | | 累计已回购股数占总股本比例 | 0.004% | | | | | | | | 累计已回购金额 | 1,831.39万元 | | | | | | | | 实际回购价格区间 | 67.75元 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-138 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司瑞石生物医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发关于 RSS0393 软膏的《药物临床试验批准通知书》，将于近期开展临床试验。现将相 关情况公告如下： 一、药物的基本情况 药物名称：RSS0393 软膏 江苏恒瑞医药股份有限公司董事会 2025 年 9 月 4 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 6 月 11 日受理的 RSS0393 软膏临床试验申请符合药品注册的有关要求，同意 本品开展临床试验，申请的适应症为用于特应性皮炎的治疗。 二、药物的其他情况 RSS0393 软膏是公司自主研发的含 PDE4 小分子抑制剂的软膏，涂抹后可通 过抑制多种细胞内的 PDE4 活性，缓解组织损伤和炎症。针对特应性皮炎，目前 全 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-139 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）及子公司福建盛迪 医药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发关 于 HRS-4729 注射液的《药物临床试验批准通知书》，将于近期开展临床试验。 现将相关情况公告如下： 药物名称：HRS-4729 注射液 剂 型：注射剂 申请事项：临床试验 受 理 号：CXHL2500558、CXHL2500559 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 6 月 11 日受理的 HRS-4729 注射液临床试验申请符合药品注册的有关要求，同 意本品开展临床试验，申请的适应症为代谢相关脂肪性肝病/代谢相关脂肪性肝 炎。 二、药物的其他情况 HRS-4729 注射液是公司自主研发的多肽类药物，是一种胰高血糖素样肽-1 受体（GLP-1R）/葡萄糖依赖性 ...

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-4729 injection, a self-developed peptide drug aimed at improving metabolic regulation and weight loss [1] Group 1: Product Development - HRS-4729 injection is a triple receptor agonist targeting GLP-1R, GIPR, and GCGR, which enhances metabolic regulation compared to dual-target therapies [1] - The drug promotes energy expenditure, fatty acid oxidation, and lipid breakdown, leading to better weight loss and reduction of liver fat [1]